CPRX

Catalyst Pharmaceutical Partners, Inc. Press Releases

$2.65
*  
0.05
1.85%
Get CPRX Alerts
*Delayed - data as of Nov. 28, 2014  -  Find a broker to begin trading CPRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115
11/24/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results
11/14/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit
11/4/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and Reimbursement
10/28/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine
10/27/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals to Present Top-Line Safety and Efficacy Results From Phase 3 Firdapse Trial at 139th Annual Meeting of the American Neurological Association
10/8/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals to Present at 13th Annual BIO Investor Forum
10/2/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
9/29/2014 4:03:00 PM - GlobeNewswire


Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
9/4/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
9/3/2014 8:03:00 AM - GlobeNewswire


Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
9/2/2014 8:03:00 AM - GlobeNewswire